For U.S. Healthcare Professionals Only

header mobile logo

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

IPSEN CARES® PATIENT SUPPORT PROGRAM OFFERINGS

ipsen-cares-logo-01

Resources to support your patients' access to TAZVERIK®

icon-support-assistance

Patient Assistance 
Program (PAP)

Patients may be eligible to receive a 
limited supply of free medication if they 
are uninsured or underinsured (based on 
program eligibility criteria).

icon-support-copay

Temporary Patient Assistance 
Program (TPAP)

Helping new or existing commercial patients 
access their medication should they 
experience a change or delay in drug 
coverage.

icon-support-assistance

Patient Assistance 
Program (PAP)

Patients may be eligible to receive a limited supply of free medication if they are uninsured or underinsured (based on program eligibility criteria).

Quick-start-program-icon

Co-Pay Assistance Program

Patients with commercial health insurance may be eligible to receive co-payment assistance from Ipsen to help reduce 
out-of-pocket costs for TAZVERIK®.*

icon-support-bottle-pill

Co-Pay Assistance 

Program

Patients with commercial health insurance 
may be eligible to receive co-payment 
assistance from Ipsen to help reduce 

out-of-pocket costs for TAZVERIK®.*

copay assistance program

Medication Support 

Nurse Program

Patients prescribed TAZVERIK who are enrolled in 
IPSEN CARES can receive individualized 
support services by an IPSEN CARES nurse to 
help them through their treatment journey.

bsp-icon

Temporary Patient Assistance Program (TPAP)

Helping new or existing commercial patients access their medication should they experience a change or delay in drug coverage.

copay assistance program

Medication Support Nurse Program

Patients prescribed TAZVERIK who are enrolled in IPSEN CARES can receive individualized support services by an IPSEN CARES nurse to help them through their treatment journey.

Note: All patient support is subject to eligibility criteria and program terms and conditions. Medication Support Nurses are provided by Ipsen and do not work under the direction of the patient's healthcare provider or give medical advice. They are trained to direct patients to their provider for treatment-related advice, including referrals.

*This offer is not valid for cash-paying patients or patients currently enrolled in Medicare, Medicaid, or any other federal or state or healthcare program. Limitations apply. Void where prohibited.

Are you a healthcare professional or pharmacy looking to enroll your patient in the IPSEN CARES Co-Pay Assistance Program?

Your commercially-insured patients may be eligible to receive co-pay assistance.* Note that only patients’ prescribers and specialty pharmacies can register patients for this program.

FOR HEALTHCARE PROFESSIONALS ONLY

ipsen-cares-logo-01

If you are interested in learning more about any of the support offerings mentioned, including eligibility requirements, visit ipsencares.com or contact IPSEN CARES at 1-866-435-5677, Monday through Friday (8 AM – 8 PM ET).

View guidance on dose reductions & 
 modifications for patients taking TAZVERIK.

DOSE MODIFICATIONS

Find helpful materials to download 
about TAZVERIK.

HCP RESOURCES

IMPORTANT SAFETY INFORMATION AND INDICATIONS

Warnings and Precautions

  • Secondary Malignancies

The risk of developing secondary malignancies is increased following treatment with TAZVERIK. Across clinical trials of 758 adults who received TAZVERIK 800 mg twice daily as monotherapy, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or B-cell acute lymphoblastic leukemia (B-ALL) occurred in 1.7% of patients. One pediatric patient developed T-cell lymphoblastic lymphoma (T-LBL). Monitor patients long-term for the development of secondary malignancies.

  • Embryo-Fetal Toxicity

Based on findings from animal studies and its mechanism of action, TAZVERIK can cause fetal harm when administered to pregnant women. There are no available data on TAZVERIK use in pregnant women to inform the drug-associated risk. Administration of tazemetostat to pregnant rats and rabbits during organogenesis resulted in dose-dependent increases in skeletal developmental abnormalities in both species beginning at maternal exposures approximately 1.5 times the adult human exposure (area under the plasma concentration time curve [AUC0‑45h]) at the 800 mg twice daily dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAZVERIK and for 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for 3 months after the final dose.

Adverse Reactions

In 62 clinical study patients with epithelioid sarcoma receiving TAZVERIK 800 mg twice daily: Serious adverse reactions occurred in 37% of patients who received TAZVERIK. Serious adverse reactions occurring in ≥3% were hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress. The most common (≥20%) adverse reactions were pain (52%), fatigue (47%), nausea (36%), decreased appetite (26%), vomiting (24%), and constipation (21%).

Drug Interactions

Avoid coadministration of strong or moderate CYP3A inhibitors with TAZVERIK. If coadministration of strong or moderate CYP3A inhibitors cannot be avoided, reduce TAZVERIK dose.

Avoid coadministration of moderate or strong CYP3A inducers with TAZVERIK, which may decrease the efficacy of TAZVERIK.

Coadministration of TAZVERIK with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and reduced efficacy of CYP3A substrates.

Lactation

Because of the potential risk for serious adverse reactions from TAZVERIK in the breastfed child, advise women not to breastfeed during treatment with TAZVERIK and for one week after the final dose.

To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Please see full Prescribing Information.